Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.11, read 2026-11-03
Ethical does not pass the values gate
Price328.86 USD
Fair value354.12
Ethical score10.0/100
Value readFairas of 6 Nov 2026
Our investment reviews on this name
2026-10-22Read Markup315.49+4.2% to today ✓Markdown gives way to Markup after a 6% rise in 7 days
2026-10-15Read Markdown296.26+11.0% to today Distribution gives way to Markdown after a 6% slide in 4 weeks
2026-09-17Read Distribution313.72+4.8% to today Markup gives way to Distribution after a 7% slide in 4 weeks
2026-08-18Read Markup338.07-2.7% to today Distribution gives way to Markup after a 28% rise in 7 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Willis Towers Watson holds its Markup at $328.86. Consolidating, no directional conviction, held for 48 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 48 days
Price at the screen
$328.86
Valuation
19.93 trailing · 14.14 forward price to earnings
Values screen
FAIL· score 10.0
The Workings
Five Screens, Shown in Full
Does not pass. Business activity screen
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Business activity: Financials sector
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Willis Towers Watson does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when WTW's ethical verdict changes
Today WTW does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 6 Nov 2026: it trades at roughly a 5% discount to our $354.12 fair value, moderate competitive moat, 7.50% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 7.1% discount to the base estimate.
Where our models see it going: fair-value estimate $354.12, with a range of $279.00 to $430.31, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Broker looks cheap yet fails ethics test
Picture a firm that helps multinationals price pensions and insure supply chains across dozens of markets. Willis Towers Watson delivers steady 8 percent revenue growth, a 17 percent profit margin and 21 percent ROE at a forward multiple of 13.2 times. The numbers look workable and the consensus target sits above the current price, yet we pass.
The decision rests on the ethical screen. The business fails the activity test and that single breach overrides any margin of safety or moderate moat. We do not need to debate valuation when the core activity screen already rules the name out.
Risks remain ordinary for the sector: currency moves, regulatory shifts and client concentration. None of those change the ethical outcome. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to United Kingdom and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
WTW trades on a US exchange (the company is based in United Kingdom). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup$337.37+3.8%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (19 analysts) rates it buy, with a mean price target of $373.
2026-10-29Markup$325.01+3.0%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (19 analysts) rates it buy, with a mean price target of $371.
2026-10-22Markup · changed$315.49+6.5%Entry 8
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (19 analysts) rates it buy, with a mean price target of $371.
2026-10-15Markdown · changed$296.26+1.4%Entry 7
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (19 analysts) rates it buy, with a mean price target of $371.
2026-10-02Distribution$292.11-6.9%Entry 6
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (19 analysts) rates it buy, with a mean price target of $377.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (19 analysts) rates it buy, with a mean price target of $380.
2026-08-18Markup · changed$338.07+28.3%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 28.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (19 analysts) rates it buy, with a mean price target of $332.
2026-07-18Distribution$263.54+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 10%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (19 analysts) rates it buy, with a mean price target of $332.
2026-07-03Distribution$263.54+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$263.54Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
